Prognostic Value of Des-Gamma-Carboxy Prothrombin in AFP-Negative Hepatocellular Carcinoma Patients Following Liver Resection: A Multicenter Study.

IF 3.3 3区 医学 Q2 ONCOLOGY
Journal of Cancer Pub Date : 2025-06-12 eCollection Date: 2025-01-01 DOI:10.7150/jca.112394
Si-Yu Liu, Mu-Gen Dai, Wen-Feng Lu, Lei Liang, Jun-Wei Liu, Zhuo-Kai Li, Bin Ye
{"title":"Prognostic Value of Des-Gamma-Carboxy Prothrombin in AFP-Negative Hepatocellular Carcinoma Patients Following Liver Resection: <i>A Multicenter Study</i>.","authors":"Si-Yu Liu, Mu-Gen Dai, Wen-Feng Lu, Lei Liang, Jun-Wei Liu, Zhuo-Kai Li, Bin Ye","doi":"10.7150/jca.112394","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Hepatocellular carcinoma (HCC) is a major global health concern with high postoperative recurrence rates. Des-gamma-carboxy prothrombin (DCP) is a promising biomarker for HCC prognosis, but its optimal cutoff value remains unclear, especially in AFP-negative patients. This study aimed to determine the ideal cutoff value of DCP in AFP-negative HCC patients following liver resection and to investigate its impact on long-term outcomes. <b>Methods:</b> This multicenter retrospective study included 661 patients who underwent curative HCC resection between 2015 and 2020 at three Chinese hospitals. Patients with AFP levels < 20 ng/mL were included. The primary endpoints were overall survival (OS) and time to recurrence (TTR). DCP levels were categorized as low (≤ 600 mAU/ml) and high (> 600 mAU/ml). <b>Results:</b> Among the 661 patients (median age 56 years; 88.4% men), 477 had low DCP levels and 184 had high DCP levels. Patients with high DCP levels had more aggressive tumor characteristics, including larger tumor size, microvascular invasion, and macrovascular invasion. The 5-year OS rates were 76.3% in the low DCP group vs. 57.6% in the high DCP group (<i>P</i> < 0.001), and the 5-year recurrence rates were 44.9% vs. 61.0% (<i>P</i> < 0.001), respectively. Multivariable analysis showed that high DCP levels were an independent risk factor for decreased OS (HR 1.548, 95%CI 1.135-2.111; <i>P</i> = 0.006) and increased TTR (HR 1.390, 95%CI 1.081-1.787; <i>P</i> = 0.010). <b>Conclusion:</b> A DCP cutoff value of 600 mAU/ml effectively stratifies AFP-negative HCC patients into high- and low-risk groups for survival and recurrence after liver resection. This cutoff value can guide clinical decision-making and improve prognostic accuracy.</p>","PeriodicalId":15183,"journal":{"name":"Journal of Cancer","volume":"16 8","pages":"2680-2689"},"PeriodicalIF":3.3000,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12171001/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7150/jca.112394","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Hepatocellular carcinoma (HCC) is a major global health concern with high postoperative recurrence rates. Des-gamma-carboxy prothrombin (DCP) is a promising biomarker for HCC prognosis, but its optimal cutoff value remains unclear, especially in AFP-negative patients. This study aimed to determine the ideal cutoff value of DCP in AFP-negative HCC patients following liver resection and to investigate its impact on long-term outcomes. Methods: This multicenter retrospective study included 661 patients who underwent curative HCC resection between 2015 and 2020 at three Chinese hospitals. Patients with AFP levels < 20 ng/mL were included. The primary endpoints were overall survival (OS) and time to recurrence (TTR). DCP levels were categorized as low (≤ 600 mAU/ml) and high (> 600 mAU/ml). Results: Among the 661 patients (median age 56 years; 88.4% men), 477 had low DCP levels and 184 had high DCP levels. Patients with high DCP levels had more aggressive tumor characteristics, including larger tumor size, microvascular invasion, and macrovascular invasion. The 5-year OS rates were 76.3% in the low DCP group vs. 57.6% in the high DCP group (P < 0.001), and the 5-year recurrence rates were 44.9% vs. 61.0% (P < 0.001), respectively. Multivariable analysis showed that high DCP levels were an independent risk factor for decreased OS (HR 1.548, 95%CI 1.135-2.111; P = 0.006) and increased TTR (HR 1.390, 95%CI 1.081-1.787; P = 0.010). Conclusion: A DCP cutoff value of 600 mAU/ml effectively stratifies AFP-negative HCC patients into high- and low-risk groups for survival and recurrence after liver resection. This cutoff value can guide clinical decision-making and improve prognostic accuracy.

des - γ -羧基凝血酶原在肝切除术后afp阴性肝癌患者中的预后价值:一项多中心研究。
背景:肝细胞癌(HCC)是全球主要的健康问题,术后复发率高。des - γ -羧基凝血酶原(DCP)是一种很有前景的HCC预后生物标志物,但其最佳临界值尚不清楚,特别是在afp阴性患者中。本研究旨在确定afp阴性HCC患者肝切除术后DCP的理想临界值,并探讨其对长期预后的影响。方法:这项多中心回顾性研究纳入了2015年至2020年在中国三家医院接受根治性HCC切除术的661例患者。纳入AFP水平< 20 ng/mL的患者。主要终点是总生存期(OS)和复发时间(TTR)。DCP水平分为低(≤600 mAU/ml)和高(≤600 mAU/ml)。结果:661例患者(中位年龄56岁;88.4%男性),477例低DCP水平,184例高DCP水平。DCP水平高的患者肿瘤具有更强的侵袭性特征,包括肿瘤体积更大、微血管侵袭和大血管侵袭。低DCP组5年OS为76.3%,高DCP组为57.6% (P < 0.001); 5年复发率为44.9%,高DCP组为61.0% (P < 0.001)。多变量分析显示,高DCP水平是OS下降的独立危险因素(HR 1.548, 95%CI 1.135-2.111;P = 0.006), TTR升高(HR 1.390, 95%CI 1.081 ~ 1.787;P = 0.010)。结论:600 mAU/ml的DCP临界值可以有效地将afp阴性HCC患者分为高危和低危组,以判断患者的生存和肝切除术后的复发情况。该截止值可指导临床决策,提高预后准确性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Cancer
Journal of Cancer ONCOLOGY-
CiteScore
8.10
自引率
2.60%
发文量
333
审稿时长
12 weeks
期刊介绍: Journal of Cancer is an open access, peer-reviewed journal with broad scope covering all areas of cancer research, especially novel concepts, new methods, new regimens, new therapeutic agents, and alternative approaches for early detection and intervention of cancer. The Journal is supported by an international editorial board consisting of a distinguished team of cancer researchers. Journal of Cancer aims at rapid publication of high quality results in cancer research while maintaining rigorous peer-review process.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信